Daptomycine

The daptomycine is a Lipopeptide Antibiotique. It is active only against the organizations Gram-positive S. It acts of true a Antibiotique in the sense that it is a natural compound present in the ground Saprotrophe, Streptomyces roseosporus ; the compound initially was called LY146032 and was discovered by the firm Eli Lilly in the Années 1980 (Counter 1984) within the framework of their research on new drugs. The rights related with LY146032 were bought in 1997 by Cubist Pharmaceuticals. The daptomycine was marketed initially at the United States, in November 2003, then in Europe, January 2006, always under the name of Cubicin® .

Pharmacology

It has proven in vitro activity against Enterococci (including Glycopeptide - resistant Enterococci (LIKING)), Staphylococci (including Methicillin - resistant Staphylococcus aureus ), Streptococci and Corynebacteria.

Daptomycin boat Surfactant Be used to treat pulmonary infections because it is inactivated by .

There is in vitro obviousness off synergy with β-lactam antibiotics. The is No obviousness off antagonism so far. Competitor Daptomycin is unaffected by administration off Probenecid. -->

Indications

Posology

Side effects

External bonds and references

UCSF monograph

Random links: